NCT02790125View on ClinicalTrials.gov

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 28, 2016

Primary Completion Date

November 7, 2017

Study Completion Date

November 7, 2017

Conditions
Healthy
Interventions
DRUG

BMS-986166

DRUG

Placebo matching BMS-986166

Trial Locations (1)

78744

PPD Development, LLC, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY